CAR T-Cell Tx Offers Good Outcomes in Refractory NHL – MedPage Today
OncLive |
CAR T-Cell Tx Offers Good Outcomes in Refractory NHL
MedPage Today WASHINGTON — The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell, axicabtagene ciloleucel demonstrated significant clinical benefit, and an acceptable safety profile in patients with refractory aggressive non-Hodgkin lymphoma (NHL), … CAR T-Cell Response Rate Tops 80% in NHL Trial |
